E-ISSN: 2619-9467

Contents    Cover    Publication Date: 28 Jun 2024
Year 2024 - Volume 34 - Issue 2

Open Access

Peer Reviewed

ORIGINAL RESEARCH
130 Viewed135 Downloaded

Tumor Burden of Non-bulky Metastatic Lymph Nodes in Endometrial Cancer: A Retrospective Cohort Study

Full Text PDF  
JCOG. 2024;34(2):67-72
DOI: 10.5336/jcog.2024-102726
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: Evaluation of the diagnostic superiority of systematic lymphadenectomy in endometrial cancer cases in conditions of sentinel lymph node (SLN) dissection cannot be performed. Material and Methods: The file records of 853 patients with endometrial cancer were reviewed in the gynecological oncology clinic of Kanuni Sultan Süleyman Hospital between 2008 and 2020. Thirty nine endometrial cancer patients with lymph node involvement were selected to study. Pelvic and paraaortic lymph node counts, positive lymph node ratios, metastatic lymph node sizes and percentages of tumor infiltration in lymph nodes were defined. Clinicopathological variables, including the categorical data, were analyzed as a descriptive method. Results: Grossly suspicious lymph nodes were observed in 46.2% of the patients. While 54.4% of metastatic lymph nodes were <1 cm (non-palpable), 12% of them <5 mm. In 17.9% of patients, all dissected metastatic lymph nodes were <1 cm (non-palpable). Conclusion: In clinics that can not performed SLN procedure in endometrial cancer, extent of lymphadenectomy may vary as a systemic lymphadenectomy or selective palpable lymph node excision depends on surgeon preference and patient morbidity. With comprehensive lymphadenectomy, occult lymph node metastasis can be detected and adding adjuvant chemoradiotherapy allows the patients to be given better survival rates in Stage IIIc disease.
REFERENCES:
  1. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60(8 Suppl):2035-41. [Crossref]  [PubMed] 
  2. Ayhan A, Tuncer ZS, Tuncer R, Yüce K, Küçükali T. Tumor status of lymph nodes in early endometrial cancer in relation to lymph node size. Eur J Obstet Gynecol Reprod Biol. 1995;60(1):61-3. [Crossref]  [PubMed] 
  3. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39. [Crossref]  [PubMed] 
  4. ASTEC study group; Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125-36. Erratum in: Lancet. 2009;373(9677):1764. [Crossref]  [PubMed]  [PMC] 
  5. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-16. [Crossref]  [PubMed] 
  6. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375(9721):1165-72. Erratum in: Lancet. 2010;376(9741):594. [Crossref]  [PubMed] 
  7. Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol. 2008;198(4):457.e1-5; discussion 457.e5-6. [Crossref]  [PubMed] 
  8. Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384-92. [Crossref]  [PubMed] 
  9. Mariani A, Webb MJ, Rao SK, Lesnick TG, Podratz KC. Significance of pathologic patterns of pelvic lymph node metastases in endometrial cancer. Gynecol Oncol. 2001;80(2):113-20. [Crossref]  [PubMed] 
  10. Weir L, Speers C, D'yachkova Y, Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol. 2002;20(7):1793-9. [Crossref]  [PubMed] 
  11. Chan JK, Kapp DS. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol. 2007;8(9):831-41. [Crossref]  [PubMed] 
  12. Chan JK, Urban R, Cheung MK, Shin JY, Husain A, Teng NN, et al. Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer. 2007;109(12):2454-60. [Crossref]  [PubMed] 
  13. Multinu F, Ducie JA, Eriksson AGZ, Schlappe BA, Cliby WA, Glaser GE, et al. Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm. Gynecol Oncol. 2019;155(2):177-85. [Crossref]  [PubMed]  [PMC] 
  14. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295-309. Erratum in: Lancet Oncol. 2018;19(4):e184. [PubMed]  [PMC] 
  15. Polterauer S, Khalil S, Zivanovic O, Abu-Rustum NR, Hofstetter G, Concin N, et al. Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancer. Obstet Gynecol. 2012;119(6):1210-8. [Crossref]  [PubMed] 
  16. Tohyama A, Murakami M, Yoshino K. Strategies for the treatment of cervical cancer with bulky pelvic lymph nodes: an overview of the current evidence. J UOEH. 2020;42(4):317-25. [Crossref]  [PubMed]